Amid heightened scrutiny of pharmaceutical industry practices, Canadian authorities have decided that Johnson & Johnson (JNJ) did not take any illegal action to thwart biosimilar competition for its best-selling Remicade medicine.
The decision comes as a growing number of countries struggling to contain the rising cost of medicines examine steps taken by drug makers to boost market share. The ruling also arrives as J&J fends off a closely watched lawsuit filed in the U.S. by Pfizer (PFE) over claims that J&J engaged in anti-competitive behavior to stifle a biosimilar version of Remicade.
About the Author Reprints
